Cargando…

Kinetics of polymerase chain reaction positivity in patients with Clostridioides difficile infection

BACKGROUND: Polymerase chain reaction (PCR) is a sensitive test for diagnosing Clostridioides difficile infection (CDI) and could remain positive following resolution of CDI. The kinetics of PCR positivity following antibiotics for CDI is unknown. We studied this and whether it predicted CDI recurre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saha, Srishti, Yadav, Devvrat, Pardi, Ryan, Patel, Robin, Khanna, Sahil, Pardi, Darrell
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504224/ https://www.ncbi.nlm.nih.gov/pubmed/34646361 http://dx.doi.org/10.1177/17562848211050443

Ejemplares similares

Incidence of Clostridioides difficile infection in peripartum women: a retrospective cohort study
por: Saha, Srishti, et al.
Publicado: (2020)

Effect of peripartum Clostridioides difficile infection on pregnancy and neonatal outcomes: an observational study
por: Saha, Srishti, et al.
Publicado: (2023)

2432. Durability Against Antibiotics After Response to Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Saha, Srishti, et al.
Publicado: (2019)

Clostridioides difficile infection: curbing a difficult menace
por: Khanna, Sahil, et al.
Publicado: (2022)

The interplay of Clostridioides difficile infection and inflammatory bowel disease
por: Sehgal, Kanika, et al.
Publicado: (2021)

Resolution rates in clinical trials for microbiota restoration for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2023)

Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2
por: Yadav, Devvrat, et al.
Publicado: (2021)

Outcomes in Patients with SARS-CoV-2 and Clostridioides difficile Coinfection
por: Sehgal, Kanika, et al.
Publicado: (2021)

Novel risk factors and outcomes in inflammatory bowel disease patients with Clostridioides difficile infection
por: Voth, Elida, et al.
Publicado: (2021)

Management of Clostridioides difficile colitis: insights for the gastroenterologist
por: Saha, Srishti, et al.
Publicado: (2019)

Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2021)

1620 Extraintestinal Clostridium difficile infections: A Single Center Experience
por: Gupta, Arjun, et al.
Publicado: (2014)

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
por: Khanna, Sahil, et al.
Publicado: (2020)

In reply—Lack of Marked Association Between Gastrointestinal Symptoms and COVID-19 Mortality: An Updated Meta-analysis Based on Adjusted Effect Estimates
por: Tariq, Raseen, et al.
Publicado: (2021)

Outcomes in children with Clostridium difficile infection: results from a nationwide survey
por: Gupta, Arjun, et al.
Publicado: (2016)

Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2020)

Experience and Outcomes at a Specialized Clostridium difficile Clinical Practice
por: Tariq, Raseen, et al.
Publicado: (2017)

Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2018)

A268 RESOLUTION RATES IN OPEN-LABEL VERSUS RANDOMIZED CONTROLLED TRIALS FOR MICROBIOTA RESTORATION FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION: AN UPDATED META-ANALYSIS
por: Tariq, R, et al.
Publicado: (2023)

Fecal microbiota transplant via colonoscopy may be preferred due to intraprocedure findings
por: Cho, Janice M., et al.
Publicado: (2019)

Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations
por: Khanna, Sahil, et al.
Publicado: (2021)

Tetracyclines are Associated with a Reduced Risk of Clostridium difficile Infection: A Systematic Review and Meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2017)

658. Diagnostic Testing Among Patients with Suspected Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III a Phase 3 Clinical Trial: Implications for Clinical Practice vs Clinical Trials
por: Sims, Matthew, et al.
Publicado: (2021)

Management of Clostridioides difficile infection in patients with inflammatory bowel disease
por: Khanna, Sahil
Publicado: (2021)

Immune response against Clostridioides difficile and translation to therapy
por: Sehgal, Kanika, et al.
Publicado: (2021)

The interplay of SARS-CoV-2 and Clostridioides difficile infection
por: Khanna, Sahil, et al.
Publicado: (2021)

Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022)

Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface
por: Sehgal, Kanika, et al.
Publicado: (2021)

The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection
por: Seekatz, Anna Maria, et al.
Publicado: (2022)

Genetic Relatedness of 5-Year Isolates of Clostridioides difficile Polymerase Chain Reaction Ribotype 017 Strains in a Hospital
por: Kim, Jieun, et al.
Publicado: (2021)

Evaluating outpatient diagnostic stewardship of comprehensive polymerase chain reaction Clostridioides difficile testing in a regional health system
por: Golovaty, Ilya, et al.
Publicado: (2023)

Antisense inhibition of RNA polymerase α subunit of Clostridioides difficile
por: Pal, Rusha, et al.
Publicado: (2023)

The natural history of histological changes in microscopic colitis
por: Sehgal, Kanika, et al.
Publicado: (2023)

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
por: McGovern, Barbara H, et al.
Publicado: (2020)

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
por: Orenstein, Robert, et al.
Publicado: (2023)

The impact of corticosteroid use on inpatients with inflammatory bowel disease and positive polymerase chain reaction for Clostridium difficile
por: Lim, Huei-Wen, et al.
Publicado: (2019)

655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection
por: Kelly, Colleen R, et al.
Publicado: (2023)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
por: Sims, Matthew D., et al.
Publicado: (2023)

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r1pr3j2agkeaqd8v86kud4kluh